Asthma – Unmet Need – Unmet Need – Severe Asthma (US/EU)
Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer Ingelheim’s Spiriva), LABA/ICS FDCs (e.g., GSK’s Advair, AZ’s Symbicort), LABA/LAMA/ICS FDCs (e.g., GSK’s Trelegy, Chiesi’s Trimbow, AZ’s Breztri), and novel biologics (e.g., AstraZeneca’s Fasenra, Teva’s Cinqair / Cinqaero, Sanofi / Regeneron’s Dupixent, GSK’s Nucala and Exdensur, AZ / Amgen’s Tezspire), effective therapies for severe disease are still needed, especially for patients whose symptoms are not adequately controlled with current therapies or who depend on frequent SABA and/or oral corticosteroid use. This Unmet Need report provides quantitative insights into key treatment drivers, therapeutic goals, and the current level of unmet need in severe asthma, based on the perceptions of U.S. and European physicians.
Questions answered
- What are the treatment drivers and goals for severe asthma?
- Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for severe asthma?
- What are the prevailing areas of unmet need and opportunity in severe asthma?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European physicians for a hypothetical new drug for severe asthma?
Product description
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Geography
United States, France, Germany, United Kingdom
Primary research
Survey of 30 U.S. and 32 EU pulmonologists, and 30 U.S. allergists
Key drugs covered
Exdensur, Nucala, Fasenra, Dupixent, Tezspire
Key analyses
- Importance of clinical and nonclinical product attributes to physicians
- Assessment of current drug performance against treatment drivers and goals
- Physician perceptions of unmet needs in the indication and related indications
- Remaining drug development opportunities
Key feature
Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
